MA-ULTIVUE
15.3.2022 16:02:09 CET | Business Wire | Press release
Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to accelerate the pace of immunotherapy and targeted therapy development, announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and Biopharma.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. “Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities offered by Sirona Dx. We believe this joint offering will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.” said Mark Rees, Ph.D. Vice President Corporate Development at Ultivue.
Sirona Dx are original pioneers of spatial biology, having launched ultra-high parameter, multiplexed imaging services to Biopharma in 2018. Their technology agnostic, full service, spatial biology suite, contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“We are delighted to announce this partnership with Ultivue” said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx. “Since 2018, clients have relied on our leading expertise to develop and implement customized, high performance multiplexed imaging panels of up to 40 markers. Having cast a wide net to identify the most informative tissue biomarker signatures, we can now harness Ultivue’s powerful InSituPlex® technology to rapidly develop, robustly validated mid-plex panels of up to 12 markers enabling our clients to accelerate their drug development programs with transformative biomarker capabilities.
About Sirona Dx
Sirona Dx is a technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research our laboratory offers specialized high complexity, single cell proteomics and genomics services supporting pharmaceutical companies with their drug discovery and development programs. Learn more at Sironadx.com.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ (NYSE: NIQ) Unveils Six New AI-Powered Capabilities at C360, Executing on Its Vision for Agentic Commerce9.6.2026 21:00:00 CEST | Press release
New capabilities help organizations operationalize trusted market intelligence across enterprise AI environments and workflows, while preparing for the future of agentic commerce NielsenIQ (NYSE: NIQ) today unveiled six new AI-powered capabilities at C360, the company's flagship client and industry event, marking a major milestone in the execution of NIQ’s AI strategy. Thenew capabilities help brands, retailers, and other organizations operationalize trusted market intelligence across enterprise workflows, AI environments, and the emerging world of agentic commerce. NIQ’s AI value creation strategy is built on two foundational principles: Delivering The Full View™: Combining the industry’s broadest and deepest datasets, advanced AI models, and rich content to help organizations unlock actionable insights and drive AI innovation at scale. Enabling AI-Powered Capabilities: Delivering trusted intelligence and proprietary IP through NIQ’s advanced AI applications, assistants, and agents em
H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology9.6.2026 17:31:00 CEST | Press release
Production-conforming systems manufactured in a regulator-approved facility mark H55’s transition from technology development to commercialization of certification-grade energy storage solutions for hybrid-electric aviation. H55 today announced the delivery of certification-grade propulsion battery modules to Pratt & Whitney Canada in support of the RTX Hybrid-Electric Flight Demonstrator — a milestone that further validates H55’s transition from technology development to industrial-scale execution and represents an important step in the commercialization of the company’s certification-grade energy storage technologies for hybrid-electric aerospace applications. Pratt & Whitney is an RTX business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609825006/en/ H55 Adagio Battery Modules in Pratt & Whitney Canada Hangar ©RTX The delivery represents more than hardware integration. It demonstrates H55’s ability to manufacture p
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
RevBits and Stony Brook University’s Ethos Lab Establish a Collaborative Partnership to Further the Field of Cyber Security Education and Application9.6.2026 16:15:00 CEST | Press release
Through the partnership, RevBits will provide its full suite of cybersecurity solutions to Stony Brook University’s Ethos Lab, to deliver the capability to advance student education and equip them with the knowledge needed to face modern cyber threats in a realistic, contained environment. Stony Brook University’s (SBU) Ethos Lab, in the College of Engineering and Applied Sciences Department of Computer Science, recently announced a collaborative partnership with RevBits, LLC. Through the partnership, SBU’s Ethos Lab will utilize the RevBits solutions suite to build computer science labs and a cybersecurity-focused curriculum, reinforcing lessons from the classroom. The platform simulates environments containing five major threat landscapes, including Endpoint Security, Privileged Access Management, Email Security, Zero Trust Network and Deception Technology. SBU’s Department of Computer Science was recently designated as a National Center of Academic Excellence in Cybersecurity Resear
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom